{"organizations": [], "uuid": "d58e7d88ab78d1ba67b77c80ff0e48ca14232d30", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180108.html", "section_title": "Archive News &amp; Video for Monday, 08 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-astellas-pharma-says-application-o/brief-astellas-pharma-says-application-of-marketing-approval-for-blinatumomab-in-japan-idUSL4N1P41AH", "country": "US", "domain_rank": 408, "title": "BRIEF-Astellas Pharma says application of marketing approval for blinatumomab in Japan", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.535, "site_type": "news", "published": "2018-01-09T09:36:00.000+02:00", "replies_count": 0, "uuid": "d58e7d88ab78d1ba67b77c80ff0e48ca14232d30"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-astellas-pharma-says-application-o/brief-astellas-pharma-says-application-of-marketing-approval-for-blinatumomab-in-japan-idUSL4N1P41AH", "ord_in_thread": 0, "title": "BRIEF-Astellas Pharma says application of marketing approval for blinatumomab in Japan", "locations": [], "entities": {"persons": [], "locations": [{"name": "japan", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "brief-astellas pharma", "sentiment": "negative"}, {"name": "astellas pharma inc", "sentiment": "negative"}, {"name": "amgen astellas biopharma", "sentiment": "none"}, {"name": "beijing headline news", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 9 (Reuters) - Astellas Pharma Inc\n* Says it announced that an application was submitted in Japan for the marketing authorization for bispecific CD19-directed CD3 T cell engager (BiTEÂ®) antibody construct blinatumomab to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia\n* In Japan, blinatumomab is jointly developed by Amgen Astellas BioPharma and the co\nSource text in Japanese: goo.gl/iGVamQ\nFurther company coverage: (Beijing Headline News)\n ", "external_links": ["https://goo.gl/iGVamQ", "http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-09T09:36:00.000+02:00", "crawled": "2018-01-09T17:11:22.000+02:00", "highlightTitle": ""}